A method for selecting a therapy to improve cognition or to prevent cognitive decline or dysfunction of a subject with Alzheimer's Disease based on a blood, plasma, or serum sample obtained from the subject, the method comprising: measuring an expression level of protein biomarkers TNFα and CRP in the sample; optionally measuring an expression level of one or more protein biomarkers in the sample, wherein the one or more protein biomarkers are selected from IL7, IL5, IL6, IL10, TNC, ICAM1, FVII, 1309, TNFR1, A2M, TARC, eotaxin3, VCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, Aβ, tau, and α-synuclein; determining a tertile of the level of expression of TNFα and CRP, and optionally one or more protein biomarkers selected from IL7, IL5, IL6, IL10, TNC, ICAM1, FVII, 1309, TNFR1, A2M, TARC, eotaxin3, VCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, Aβ, tau, and α-synuclein; and depending on the level of expression dividing the level of expression of the two or more biomarkers as being either high proinflammatory or low proinflammatory; and selecting a course of treatment for the subject, wherein: if the subject is scored in the tertile that is scored as high proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is indicated; if the subject is scored in the tertile that is scored as low proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is contraindicated; wherein the tertile is determined by: scoring the tertile scores for the two or more biomarkers to generate a score with a range from two to six, assigning a lower score to a low end of the proinflammatory, assigning a highest score to a high end of the proinflammatory, with all other scores falling in a middle score. measuring an expression level of protein biomarkers TNFα and CRP in the sample; optionally measuring an expression level of one or more protein biomarkers in the sample, wherein the one or more protein biomarkers are selected from IL7, IL5, IL6, IL10, TNC, ICAM1, FVII, 1309, TNFR1, A2M, TARC, eotaxin3, VCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, Aβ, tau, and α-synuclein; determining a tertile of the level of expression of TNFα and CRP, and optionally one or more protein biomarkers selected from IL7, IL5, IL6, IL10, TNC, ICAM1, FVII, 1309, TNFR1, A2M, TARC, eotaxin3, VCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, Aβ, tau, and α-synuclein; and depending on the level of expression dividing the level of expression of the two or more biomarkers as being either high proinflammatory or low proinflammatory; and selecting a course of treatment for the subject, wherein: if the subject is scored in the tertile that is scored as high proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is indicated; if the subject is scored in the tertile that is scored as low proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is contraindicated; wherein the tertile is determined by: scoring the tertile scores for the two or more biomarkers to generate a score with a range from two to six, assigning a lower score to a low end of the proinflammatory, assigning a highest score to a high end of the proinflammatory, with all other scores falling in a middle score. if the subject is scored in the tertile that is scored as high proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is indicated; if the subject is scored in the tertile that is scored as low proinflammatory, selecting for the subject an anti-inflammatory treatment selected from NSAIDs, non-selective NSAIDs, selective NSAIDs, steroids, glucocorticoids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti-TNF medications, anti-IL5 drugs or CRP-lowering agents is contraindicated; wherein the tertile is determined by: scoring the tertile scores for the two or more biomarkers to generate a score with a range from two to six, assigning a lower score to a low end of the proinflammatory, assigning a highest score to a high end of the proinflammatory, with all other scores falling in a middle score. scoring the tertile scores for the two or more biomarkers to generate a score with a range from two to six, assigning a lower score to a low end of the proinflammatory, assigning a highest score to a high end of the proinflammatory, with all other scores falling in a middle score.